EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment

Weihong Ding iD, Xinyue Zhang, Hongdan Wu, Congrui Zhou, Ke Xu, Zongguang Tai iD, Guowei Xia

International Journal of Nanomedicine · 2026

DOI: 10.2147/ijn.s616713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Weihong Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Nanoparticles, Janus Kinase 2, Janus Kinase 1. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Although inhibition of the JAK-STAT signaling pathway has shown promise in cancer therapy, the therapeutic potential of PROTAC-mediated JAK1/JAK2 degradation in bladder cancer remains to be fully explored. To improve the delivery and therapeutic efficacy of PROTAC-mediated JAK1/JAK2 degradation in bladder cancer, this study developed PPcJ, a cRGD-functionalized PLGA-PEG nanoparticle encapsulating the PROTAC-based JAK1/JAK2 degrader JAPT8.

Methods

PPcJ nanoparticles were characterized using transmission electron microscopy, dynamic light scattering, and high-performance liquid chromatography. Flow cytometry and confocal microscopy were used to evaluate cytotoxicity, anti-tumor effect, and intracellular localization, while Western blotting assessed the expression of JAK/STAT pathway and apoptosis-related proteins. In vivo tumor-associated fluorescence, antitumor efficacy, survival, histopathology, and serum biochemical parameters were assessed in tumor-bearing mice.

Results

PPcJ exhibited a spherical nanoscale morphology. PPcJ achieved near-plateau cellular uptake at low concentrations and partially evaded lysosomal degradation, which significantly induced apoptosis in bladder cancer cells and suppressed key components of the JAK/STAT signaling pathway. In vivo, cRGD modification enabled higher tumor-specific accumulation and prolonged retention. PPcJ inhibited tumor growth by 86.2% and prolonged mean survival from 22.4 ± 4.2 to 41.0 ± 2.2 days, without significant changes in body weight, major-organ histology, or serum AST, ALT, urea, and creatinine levels under the tested conditions.

Conclusion

These findings provide a preclinical proof-of-concept that the PPcJ nano-delivery system improves the delivery and antitumor performance of JAPT8. This strategy warrants further evaluation in systemic therapeutic approaches for bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsNanoparticlesJanus Kinase 2Janus Kinase 1Antineoplastic AgentsAnimalsProteolysis Targeting ChimeraHumansCell Line, TumorMicePolyethylene GlycolsApoptosisSignal TransductionFemaleMice, NudeXenograft Model Antitumor AssaysMice, Inbred BALB C

Stichwörter der Autor:innen

JAK/STAT signalingJAPT8PLGA-PEGdrug delivery systemurothelial carcinoma

Substanzen

Proteolysis Targeting ChimeraJanus Kinase 2Janus Kinase 1Polyethylene GlycolsAntineoplastic AgentsJAK2 protein, human

Autor:innen und Institutionen

  • Department of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China.
  • Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, People's Republic of China.

ORCID-Profile: Weihong Ding, Zongguang Tai

Zitieren

APA

Ding, W., Zhang, X., Wu, H., Zhou, C., Xu, K., Tai, Z., & Xia, G. (2026). Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s616713

Vancouver

Ding W, Zhang X, Wu H, Zhou C, Xu K, Tai Z, et al. Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s616713

BibTeX
@article{Ding2026,
  author = {Ding, Weihong and Zhang, Xinyue and Wu, Hongdan and Zhou, Congrui and Xu, Ke and Tai, Zongguang and Xia, Guowei},
  title = {Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  doi = {10.2147/ijn.s616713}
}
Kostenlos starten →